A study by Kaptein et al. found that IL-2, anti-CTLA-4, and anti-PD1 triple immunotherapy was able to convert anti-CTLA4 + anti-PD1 non-responders to responders in ex vivo patient melanoma tumors [33]. The gene discussed is IL2; the disease is melanoma.